Cavion is developing oral small molecules designed to selectively modulate T-type calcium channel activity in the central nervous system, acting as a biological "pacemaker" to help restore the brain's natural rhythms.
The company's lead candidate CX-8998 is a first-in-class T-type calcium channel modulator and is the most advanced late-stage small molecule currently in development for essential tremor.
CX-8998 was evaluated in the T-CALM Study, a Phase 2, double-blind, placebo-controlled clinical trial of 95 patients with essential tremor conducted at 25 sites across the United States.
Patients were randomised to one of two treatment arms, receiving either placebo or CX-8998. A majority of subjects took study drug on top of certain standard of care anti-tremor medications.
Cavion is a privately held clinical stage biotechnology company creating therapies aimed at modulating the T-type calcium channel for the treatment of chronic and rare neurological diseases.
The company's portfolio of T-type calcium channel modulators is being developed to restore the brain's natural rhythms in a variety of neurological diseases such as essential tremor, Parkinson's disease tremor, neuropathic pain, and epilepsy with absence seizures.
About 10m Americans and 42 m people worldwide are affected by essential tremor, the most common movement disorder.
ET is a progressive neurodegenerative disease that ranges from mild to fully debilitating, with significant effects on people's quality of life and activities of daily living, such as eating and drinking, dressing, writing and typing.
The condition can lead to social embarrassment, phobia, anxiety, and depression.
With no new drugs approved for more than three decades, there is a need for new and effective options for patients with ET.
Hikma announces Health Canada approval of KLOXXADO Nasal Spray for opioid overdose treatment
Plus Therapeutics secures FDA Orphan Drug Designation for Rhenium (186Re) Obisbemeda
Latigo Biotherapeutics' LTG-001 receives US FDA Fast Track designation
GenSight Biologics reports positive five-year resultsfor LUMEVOQ gene therapy
Bain Capital to acquire Mitsubishi Tanabe Pharma in USD3.3bn deal
Innovent and ASK Pharm's limertinib NDA receives Chinese regulatory approval
Anavex reports positive long-term data for blarcamesine in early Alzheimer's disease
Johnson & Johnson agrees acquisition of Intra-Cellular Therapies Inc
Neuraxpharm acquires Provigil and Nuvigil to expand CNS portfolio
Nuvation Bio secures NMPA approval for taletrectinib in China
JCR Pharmaceuticals and Modalis Therapeutics advance to next phase of joint gene therapy research
PTC Therapeutics submits vatiquinone NDA to US FDA
Mitsubishi Tanabe Pharma forms research collaboration with Dewpoint Therapeutics
IXICO signs commercial agreement with PETNET Solutions to enhance neuroimaging capabilities